Xu Cong Claire
SEC CIK 2114309 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NBP | NovaBridge Biosciences | SVP, Clinical Development | 304.2K | — | $20.4K | 6 | 2026-05-30 | 2026-08-31 |
Most active insiders at NBP, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Hagler Mark Arnold | See Remarks | $577.3K | — |
| 2 | Cao Sean Wuxiong | See Remarks, Dir | — | $122.5K |
| 3 | Xu Cong Claire | SVP, Clinical Development | — | $20.4K |
| 4 | Dennis Phillip Andrew | Chief Medical Off | — | $11.4K |
| 5 | Lenz Robert A. | Dir | — | — |
Transactions 6
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-01 18:00 | 2026-08-30 | NBP | NovaBridge Biosciences | Xu Cong Claire | EVP, Clinical Development | M - OptEx | — | +9,382 | 307.5K | +3% | — |
| D | 2026-09-01 18:00 | 2026-08-31 | NBP | NovaBridge Biosciences | Xu Cong Claire | EVP, Clinical Development | S - Sale+OE | $0.79 | -3,282 | 304.2K | -1% | -$2,593 |
| D | 2026-07-07 19:50 | 2026-07-04 | NBP | NovaBridge Biosciences | Xu Cong Claire | SVP, Clinical Development | M - OptEx | — | +12.4K | 302.6K | +4% | — |
| D | 2026-07-07 19:50 | 2026-07-06 | NBP | NovaBridge Biosciences | Xu Cong Claire | SVP, Clinical Development | S - Sale+OE | $0.89 | -4,485 | 298.1K | -1% | -$3,992 |
| D | 2026-06-02 18:46 | 2026-05-30 | NBP | NovaBridge Biosciences | Xu Cong Claire | SVP, Clinical Development | M - OptEx | — | +9,382 | 293.6K | +3% | — |
| D | 2026-06-02 18:46 | 2026-06-01 | NBP | NovaBridge Biosciences | Xu Cong Claire | SVP, Clinical Development | S - Sale+OE | $3.94 | -3,494 | 290.2K | -1% | -$13.8K |
Purchase Sale Sale after option exercise All abbreviations